Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluzoparib + tislelizumab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
fluzoparib + tislelizumab is a combination therapy being investigated for the treatment of advanced squamous non-small cell lung cancer (NSCLC). Fluzoparib is a potent small molecule inhibitor of poly (ADP-ribose) polymerase enzymes 1 and 2 (PARP1/2), developed by Jiangsu Hengrui Medicine. It works by blocking DNA repair pathways, leading to genomic instability and cell death in cancer cells, particularly those with homologous recombination deficiencies. Tislelizumab, developed by BeiGene, is a humanized IgG4 monoclonal antibody directed against the programmed cell death protein 1 (PD-1) receptor. By inhibiting the PD-1/PD-L1 pathway, tislelizumab restores the ability of T cells to recognize and attack tumor cells. This combination is currently being evaluated in a Phase II clinical trial led by Tianjin Medical University Cancer Institute and Hospital as a maintenance therapy for patients with advanced squamous NSCLC who have achieved disease control following induction chemo-immunotherapy.
- Brand names
- AiRuiYiBaizean
- Other names
- fluzoparibtislelizumabTirelizumabFluzopari
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on fluzoparib + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluzoparib + tislelizumab.